CRISPR Therapeutics AG (CRSP) EBITDA (2015 - 2026)
CRISPR Therapeutics AG (CRSP) posted EBITDA of -$130.2 million for Q1 2026, up 15.84% sequentially from -$154.8 million in Q4 2025, and up 12.25% YoY from -$116.0 million in Q1 2025.
CRISPR Therapeutics AG (CRSP) EBITDA (2015 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported EBITDA for 12 years, with the latest figure at -$130.2 million in Q1 2026.
- Quarterly EBITDA rose 12.25% year-over-year to -$130.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$646.4 million (down 36.25% YoY) and the FY2025 annual result came in at -$664.6 million, down 42.44% from the prior year.
- EBITDA improved to -$130.2 million in Q1 2026 per CRSP's latest filing, from -$154.8 million in the prior quarter.
- Over five years, EBITDA peaked at $69.6 million in Q4 2023 and troughed at -$229.3 million in Q2 2025.
- A 5-year average of -$126.9 million and a median of -$132.4 million in 2023 frame the typical range for EBITDA.
- The sharpest annual moves came in 2023 and 2024: EBITDA jumped 152.9% in 2023, then tumbled 192.82% in 2024.
- Over 5 years, EBITDA stood at -$131.5 million in 2022, then soared by 152.9% to $69.6 million in 2023, then sank by 192.82% to -$64.6 million in 2024, then plunged by 139.62% to -$154.8 million in 2025, then gained by 15.84% to -$130.2 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$130.2 million, -$154.8 million, and -$132.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | -117.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -117.27 Mn |
| Mar 31, 2026 | -130.25 Mn |
| Dec 31, 2025 | -154.76 Mn |
| Sep 30, 2025 | -132.06 Mn |
| Jun 30, 2025 | -229.32 Mn |
| Mar 31, 2025 | -148.42 Mn |
| Dec 31, 2024 | -64.59 Mn |
| Sep 30, 2024 | -110.13 Mn |
| Jun 30, 2024 | -151.26 Mn |
| Mar 31, 2024 | -140.59 Mn |
| Dec 31, 2023 | 69.58 Mn |
| Sep 30, 2023 | -132.41 Mn |
| Jun 30, 2023 | -95.22 Mn |
| Mar 31, 2023 | -64.49 Mn |
| Dec 31, 2022 | -131.54 Mn |
| Sep 30, 2022 | -182.39 Mn |
| Jun 30, 2022 | -183.26 Mn |
| Mar 31, 2022 | -175.97 Mn |
| Dec 31, 2021 | -145.70 Mn |
| Sep 30, 2021 | -128.85 Mn |